Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, United States; Magee-Womens Research Institute, Pittsburgh, PA, United States.
Antiviral Res. 2013 Dec;100 Suppl(0):S17-24. doi: 10.1016/j.antiviral.2013.09.023. Epub 2013 Nov 1.
Rectal pre-exposure prophylaxis (PrEP) will be a critical component of HIV prevention products due to the prevalence of unprotected receptive anal intercourse among men who have sex with men and heterosexual couples. Given the biological considerations of this compartment and the complexity of HIV infection, design of a successful rectal microbicide product faces a number of challenges. Important information is being compiled to begin to address deficits in knowledge toward design of rectal PrEP products for men and women. Aspects of formulation development and preclinical and clinical evaluation of rectal products studied to date are summarized in this review. This article is based on a presentation at the "Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies," held in Arlington, Virginia on February 21-22, 2013. It forms part of a special supplement to Antiviral Research.
直肠暴露前预防(PrEP)将成为 HIV 预防产品的重要组成部分,因为男男性行为者和异性恋夫妇中无保护的接受性肛交很普遍。鉴于该部位的生物学考虑因素以及 HIV 感染的复杂性,成功的直肠杀微生物剂产品的设计面临许多挑战。正在汇集重要信息,以开始解决针对男性和女性直肠 PrEP 产品设计的知识不足问题。本文总结了迄今为止在直肠产品的制剂开发和临床前及临床评估方面的研究进展。本文基于 2013 年 2 月 21 日至 22 日在弗吉尼亚州阿灵顿举行的“产品开发研讨会 2013:HIV 和多用途预防技术”的一次演讲。它是抗病毒研究特刊的一部分。